NO921050L - Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister - Google Patents

Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister

Info

Publication number
NO921050L
NO921050L NO92921050A NO921050A NO921050L NO 921050 L NO921050 L NO 921050L NO 92921050 A NO92921050 A NO 92921050A NO 921050 A NO921050 A NO 921050A NO 921050 L NO921050 L NO 921050L
Authority
NO
Norway
Prior art keywords
histamine
subject
agent
receptor agonists
receptor
Prior art date
Application number
NO92921050A
Other languages
English (en)
Norwegian (no)
Other versions
NO921050D0 (no
Inventor
Jan Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Estero Anstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estero Anstalt filed Critical Estero Anstalt
Publication of NO921050D0 publication Critical patent/NO921050D0/no
Publication of NO921050L publication Critical patent/NO921050L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO92921050A 1989-09-19 1992-03-18 Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister NO921050L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19
PCT/SE1990/000599 WO1991004037A1 (en) 1989-09-19 1990-09-19 Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists

Publications (2)

Publication Number Publication Date
NO921050D0 NO921050D0 (no) 1992-03-18
NO921050L true NO921050L (no) 1992-03-18

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92921050A NO921050L (no) 1989-09-19 1992-03-18 Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister

Country Status (12)

Country Link
US (1) US5348739A (de)
EP (1) EP0493468B1 (de)
JP (1) JP2845622B2 (de)
KR (1) KR100195392B1 (de)
AT (1) ATE136786T1 (de)
AU (1) AU640954B2 (de)
CA (1) CA2066728C (de)
DE (1) DE69026620T2 (de)
DK (1) DK0493468T3 (de)
ES (1) ES2087163T3 (de)
NO (1) NO921050L (de)
WO (1) WO1991004037A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5533094A (en) * 1992-11-27 1994-06-22 Wellcome Foundation Limited, The Enzyme inhibitors
JPH10504304A (ja) * 1994-08-08 1998-04-28 マキシム ファーマシューティカルズ，インコーポレイテッド ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
JP2002523378A (ja) * 1998-08-24 2002-07-30 マキシム ファーマシューティカルズ インコーポレイテッド Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
AU779215B2 (en) * 1999-07-16 2005-01-13 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
KR20040095250A (ko) * 2002-03-29 2004-11-12 맥심 파마수티컬즈 인크. 안내 손상의 치료 및 예방에 사용하기 위한 활성 산소대사물(ｒｏｍ)의 생성 및 방출 억제제의 용도
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
JP2008531562A (ja) 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
RU2008110955A (ru) 2005-08-24 2009-09-27 Инотек Фармасьютикалз Корпорейшн (Us) Инденоизохинолиноновые аналоги и способы их применения
KR20090115879A (ko) 2007-02-28 2009-11-09 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체와 이의 이용 방법
WO2010120649A2 (en) * 2009-04-16 2010-10-21 Epicept Corporation Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formation
JP6051378B2 (ja) * 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
WO2019006133A1 (en) * 2017-06-29 2019-01-03 Immune Pharmaceuticals, Inc. METHODS OF DELAYING AND PREVENTING RECHUTE FROM ACUTE MYELOID LEUKEMIA
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
JP2845622B2 (ja) 1999-01-13
US5348739A (en) 1994-09-20
JPH05504548A (ja) 1993-07-15
CA2066728A1 (en) 1991-03-20
EP0493468A1 (de) 1992-07-08
CA2066728C (en) 2001-12-25
EP0493468B1 (de) 1996-04-17
AU640954B2 (en) 1993-09-09
KR920703078A (ko) 1992-12-17
DE69026620D1 (de) 1996-05-23
AU6419190A (en) 1991-04-18
ATE136786T1 (de) 1996-05-15
NO921050D0 (no) 1992-03-18
WO1991004037A1 (en) 1991-04-04
ES2087163T3 (es) 1996-07-16
DE69026620T2 (de) 1996-10-02
KR100195392B1 (ko) 1999-06-15
DK0493468T3 (da) 1996-08-26

Similar Documents

Publication Publication Date Title
NO921050D0 (no) Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister
Goldstein et al. The role of interferon in cancer therapy: a current perspective
GR3023511T3 (en) THE EFFECT OF N,N,N-TRIMETHYLSPHINGOSINE ON PROTEIN KINASE-C ACTIVITY; MELANOMA CELL GROWTH -i(IN VITRO); METASTATIC POTENTIAL -i(IN VIVO) AND HUMAN PLATELET AGGREGATION
Bernal et al. Membrane antigen in small cell carcinoma of the lung defined by monoclonal antibody SM1
Miller Intratumor immunologic heterogeneity
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
SE9201719D0 (sv) Preparatfoer aktivering av naturliga moerdarceller (nk-celler), vilket preparat innehaaller interferon-alfa och biogena aminer eller substanser med motsvarande receptoraktivitet
Baguley et al. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5, 6-dimethylxanthenone-4-acetic acid
Morton et al. Active specific immunotherapy in malignant melanoma
IL83804A (en) Imidazolylguanidine derivatives, processes for preparing them and pharmaceutical compositions containing them
Chiodoni et al. Different requirements for α‐galactosylceramide and recombinant IL‐12 antitumor activity in the treatment of C‐26 colon carcinoma hepatic metastases
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
NO306700B1 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
Shimizu et al. Effects of a single injection of anti‐asialo GM1 serum on natural cytotoxicity and the growth of a regressive colonic tumor in syngeneic rats
NL7701304A (nl) Stimuleermiddelen voor (beta)-adrenoreceptors en werkwijze ter bereiding daarvan.
Maeda et al. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma
Chao et al. Effect of indomethacin on tumor-infiltrating lymphocytes of a spontaneously developed murine mammary adenocarcinoma
Prete et al. Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil.
KR850006429A (ko) 새로운 시아노이미다졸 누클레오시드 유도체 및 그 제조방법
Kim et al. Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector.
IT8419390A0 (it) Nuovi derivati dell'alfa-amino-gamma-butirrolattone, metodo per prepararli e composizioni farmaceutiche che licontengono.
Sporn et al. Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2
Robins Purine nucleoside 3′, 5′-cyclic monophosphates as hormonal modulators of cellular proliferation, metastases and lymphocyte response
Voltchek et al. Comparative study of the cytostatic effects of Oliphen and Ukrain
Goltz The Graft-vs-Host Reaction: An Iatrogenic Model for a Number of Skin Disorders